| Biomarker ID | 799 |
| PMID | 22052531 |
| Year | 2011 |
| Biomarker | hsa-mir-375 |
| Biomarker Basis | Expression Based |
| Biomolecule | miRNA |
| Source | Serum |
| Subjects | Humans |
| Regulation | High expression with reduced chances of relapse free survival |
| Odds Ratio/Hazard Ratio/Relative Risk | Univariate: HR: 3.49 (95% CI: 1.82-6.69); Multivariate: 5.70 (95% CI: 1.24-26.2) |
| Effect on Pathways | Pathways Include(hsa-mir-375):-DNA-binding transcription factor activity, RNA polymerase II-specific; DNA-binding transcription factor activity; nuclear chromatin; chromatin; nuclear chromosome |
| Experiment | Biochemical Recurrenece |
| Type of Biomarker | Prognostic |
| Cohort | 128 primary prostate cancers, 29 non-malignant tissues and 14 metastases were selected for the study. GEO accession number: GSE21036 |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | concordance index (area under of the curve) = miR-375 + Gleason Score = 0.794 |
| Level Of Significance | Univariate: p=0.0001; Multivariate: p=0.0260 |
| Method Used | qRT-PCR |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | hsa-mir-375 |